OSTEOGENESIS IMPERFECTA
The purpose of this study was to investigate the efficacy of oral alendronate for the older children with osteogenesis imperfecta. Eight boys and 6 girls with average age of 9.7 years were given oral alendronate, 10mg everyday for those > 35kg, 10mg every other day for those 20 - 35 kg, and 10mg every three days for those
This study revealed beneficial effects of oral alendronate in osteogenesis imperfecta patients, supported by radiological, biochemical and histological findings. We believe that oral alendronate is a more convenient method of bisphosphonate treatment for osteogenesis imperfecta, especially in older children.
Cho, T.-J., Choi, I.H., Chung, C.Y., Park, M.S., Park, Y.K., Shin,
Department of Orthopaedic Surgery, Seoul National University Children's Hospital, Seoul, Republic of Korea
Copyright British Editorial Society of Bone & Joint Surgery 2003
Provided by ProQuest Information and Learning Company. All rights Reserved